Issue 11, 2007

Targeting neurological disease with RNAi

Abstract

The neuroscientific community rapidly adopted RNA interference techniques as an experimental tool for the dissection of gene function in vitro and in animal models of neurological disease in vivo. Here, we discuss recent advances in the biotechnical implementation of siRNA/shRNA-mediated gene silencing focusing on issues of design, delivery and putative detrimental effects. We then summarize the current use of RNAi in targeting neurological disease models and give an outlook on the implementation of this technique in clinical therapy.

Graphical abstract: Targeting neurological disease with RNAi

Article information

Article type
Highlight
First published
29 Aug 2007

Mol. BioSyst., 2007,3, 773-780

Targeting neurological disease with RNAi

P. Lingor and M. Bähr, Mol. BioSyst., 2007, 3, 773 DOI: 10.1039/B701169E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements